Dr. Leta Vega
your Educator Speaker Advocate

GLP-1 Medications and Menopause: A New Tool for Weight Management

Many women entering menopause notice that maintaining a healthy weight becomes increasingly difficult. Despite eating the same foods and maintaining similar activity levels, the number on the scale often creeps upward. For some women, the accumulation of abdominal fat can be frustrating and may increase the risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome. Recently, GLP-1 receptor agonists have emerged as a promising treatment option for weight management during and after menopause.

Why Weight Gain Occurs During Menopause

Menopause is associated with significant hormonal changes, particularly declining estrogen levels. These hormonal shifts contribute to a decrease in resting metabolic rate, loss of lean muscle mass, and increased fat storage around the abdomen. In addition, sleep disturbances, increased stress, insulin resistance, and reduced physical activity may further contribute to weight gain.

Research suggests that women gain an average of 1 to 1.5 pounds per year during the menopausal transition, with much of this weight accumulating centrally around the waist.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications originally developed to treat type 2 diabetes. Common examples include entity[“medication”,“Semaglutide”,“GLP-1 receptor agonist”] and entity[“medication”,“Tirzepatide”,“dual GIP/GLP-1 receptor agonist”].

These medications mimic naturally occurring hormones that help regulate appetite, blood sugar levels, and digestion. They work by:

• Increasing feelings of fullness
• Slowing stomach emptying
• Reducing hunger signals in the brain
• Improving insulin sensitivity
• Helping regulate blood glucose levels

As a result, many patients experience significant and sustained weight loss.

What Does the Evidence Show?

Large clinical trials have demonstrated impressive weight loss outcomes. Studies of semaglutide have shown average weight reductions of approximately 15% of total body weight over 68 weeks when combined with lifestyle interventions. Tirzepatide studies have demonstrated even greater reductions, with some participants losing more than 20% of their body weight.

Although most studies have included both men and women, postmenopausal women appear to benefit similarly from treatment. Emerging evidence suggests that weight loss achieved with GLP-1 medications may also improve several health conditions commonly associated with menopause, including hypertension, prediabetes, obstructive sleep apnea, and elevated cholesterol levels.

Important Considerations

While GLP-1 medications can be highly effective, they are not a substitute for healthy lifestyle habits. Maintaining muscle mass is particularly important during menopause. Weight loss without adequate protein intake and resistance training may contribute to muscle loss, which can further slow metabolism.

Women using GLP-1 medications should focus on:

• Consuming adequate protein
• Participating in regular resistance training
• Staying hydrated
• Prioritizing sleep
• Maintaining regular follow-up with their healthcare provider

Common side effects include nausea, constipation, diarrhea, vomiting, and abdominal discomfort. Most side effects improve as the body adjusts to treatment.

The Bottom Line

GLP-1 receptor agonists represent an important advancement in obesity and metabolic health management. For menopausal women struggling with weight gain despite lifestyle modifications, these medications may provide an effective tool to support long-term weight loss and improve overall health. However, the best outcomes occur when medication is combined with proper nutrition, strength training, and healthy lifestyle habits.

As with any treatment, women should discuss the potential benefits, risks, and costs with their healthcare provider to determine whether GLP-1 therapy is an appropriate option for their individual health needs.

Belly Fat in Menopause: Why It Happens and What You Can Do About It

One of the most frustrating changes many women notice during menopause is an increase in abdominal fat. Even women who have maintained a stable weight for years may suddenly find that their midsection is expanding. This shift is not simply about aging or lifestyle—it is closely tied to the hormonal changes that define menopause.

The primary driver is the decline in estrogen. Estrogen plays a key role in how fat is distributed in the body. During the reproductive years, fat is more likely to be stored in the hips and thighs. As estrogen levels drop, fat distribution shifts toward the abdomen, leading to what is often described as “menopausal belly.” This type of fat, known as visceral fat, surrounds internal organs and is metabolically active, meaning it carries higher risks for conditions such as cardiovascular disease, insulin resistance, and type 2 diabetes.

Metabolism also slows with age, but menopause can accelerate this process. Muscle mass naturally declines over time, and because muscle burns more calories than fat, this contributes to a lower resting metabolic rate. At the same time, sleep disturbances and increased stress, both common during menopause, can elevate cortisol levels. Higher cortisol is associated with increased fat storage, particularly in the abdominal area.

Addressing belly fat during menopause requires a strategic and multifaceted approach. Quick fixes and extreme dieting are not only ineffective long-term but can further disrupt metabolism.

Nutrition is foundational. A balanced, protein-forward diet helps preserve lean muscle mass and supports satiety. Incorporating whole foods, vegetables, fruits, lean proteins, healthy fats, and high-fiber carbohydrates, can stabilize blood sugar and reduce fat accumulation. Limiting refined sugars, ultra-processed foods, and excessive alcohol is particularly important, as these contribute to abdominal fat storage and inflammation.

Strength training is one of the most effective interventions. Resistance exercises help rebuild and maintain muscle mass, which in turn boosts metabolic rate. Women in menopause benefit from incorporating strength training at least two to three times per week. This can include free weights, resistance bands, or bodyweight exercises. Cardiovascular activities, such as brisk walking, cycling, or interval training, complements strength work by supporting heart health and increasing overall calorie expenditure.

Sleep and stress management are often overlooked but critical components. Poor sleep disrupts hunger hormones like ghrelin and leptin, increasing cravings and making weight management more difficult. Prioritizing consistent sleep routines and addressing insomnia can have a measurable impact. Similarly, stress-reduction techniques, such as mindfulness, yoga, or deep breathing, can help regulate cortisol levels.

Medical and therapeutic options may also be appropriate for some women. Hormone therapy can help address underlying estrogen deficiency and may indirectly influence fat distribution, though it is not a primary weight loss treatment. Medications for weight management or metabolic conditions may be considered based on individual health profiles. Consulting with a healthcare provider ensures that any treatment plan is both safe and effective.

It is important to set realistic expectations. The goal is not necessarily to return to a pre-menopausal body, but to improve metabolic health, strength, and overall well-being. Small, consistent changes in diet, movement, and lifestyle often yield the most sustainable results.

Belly fat in menopause is common, but it is not inevitable or untreatable. With a targeted approach that addresses hormones, metabolism, and lifestyle, women can reduce abdominal fat and protect their long-term health while navigating this transition.

Quick Hit on HRT

Hormone therapy remains the gold standard for treating menopausal hot flashes: low-dose systemic estrogen (with a progestogen if the uterus is intact) produces the most rapid and robust relief and is recommended for women without contraindications, especially if started within 10 years of menopause onset. Lippincott Journals+1

For women who cannot or choose not to use hormones, several effective nonhormonal options exist. SSRIs/SNRIs (for example, paroxetine or venlafaxine) and gabapentin reduce hot-flash frequency and severity and are well supported by randomized trials and reviews. Cochrane+1 Emerging nonhormonal neurokinin-3 (NK3) receptor antagonists (e.g., fezolinetant and newer agents) target the neural drivers of vasomotor symptoms and offer promising, rapid relief. The Menopause Society Other approaches, including low-dose oxybutynin and procedural options such as stellate-ganglion block, have growing evidence but are generally reserved for refractory cases. saaog.org+1

Recent regulatory updates have also shifted risk communication about menopausal hormone therapy, emphasizing individualized benefit–risk assessment with clinicians. HHS+1

In short: discuss goals, personal risk factors, and preferences with your clinician, as hormone therapy is most effective; nonhormonal pharmacotherapies and new targeted agents provide good alternatives when HT is unsuitable.

Peer-reviewed references

1. The North American Menopause Society. The 2023 Nonhormone Therapy Position Statement. Menopause (2023). The Menopause Society
2. Cochrane Review: Non-hormonal interventions for reducing hot flushes (2022). Cochrane
3. Witten T. et al., Nonhormonal Pharmacotherapies for Vasomotor Symptoms. PMC article (2024). PMC
4. Kling JM. Management of the Vasomotor Symptoms of Menopause. Mayo Clinic Proceedings (2024).